Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians recover from COVID-related distress. The recently launched EMBARK is a groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine. Cybin has co-sponsored the study — which will be led by Dr. Anthony Back, a recognized leader in the fields of palliative care and oncology — in a strategic collaboration with the University of Washington. The study will examine treating depression, anxiety, burnout and post-traumatic stress symptoms among frontline doctors, nurses and healthcare professionals. Dr. Back is quoted in a recent article as saying, “There is tremendous potential in a collaboration between the University of Washington and Cybin to move the field forward, and this project is an incredibly valuable initial step towards a productive future.”
To view the full article, visit https://ibn.fm/OdaGn
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.